☆ 4.7 Editorial Material

Anthracyclines and Early Breast Cancer: The End of an Era?

JOURNAL OF CLINICAL ONCOLOGY (2009)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 27, Issue 8, Pages 1155-1157

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1200/JCO.2008.20.1640

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Anthracyclines in the treatment of early breast cancer friend or foe?

Ana Tecic Vuger, Katsuki Tiscoski, Thiago Apolinario, Fatima Cardoso

Summary: This article reviews the efficacy and toxicity of anthracyclines in the treatment of early breast cancer, and discusses the need for individualized treatment.

BREAST (2022)

Add to Collection

Review Health Care Sciences & Services

MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review

Roberto Rosenfeld, Silvia Riondino, Vincenzo Formica, Francesco Torino, Eugenio Martuscelli, Mario Roselli

Summary: Breast cancer is the most common type of cancer in women, and the chemotherapy drug doxorubicin can cause heart toxicity. Early diagnosis of heart toxicity is important to prevent complications. Non-coding RNA, specifically microRNA and circular RNA, are being researched as potential biomarkers for early detection. Further studies are needed to understand the mechanisms and develop reliable detection methods.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study

Husam Abdel-Qadir, Felicia Tai, Ruth Croxford, Peter C. Austin, Eitan Amir, Oscar Calvillo-Arguelles, Heather Ross, Douglas S. Lee, Paaladinesh Thavendiranathan

Summary: This study focused on the prognosis of heart failure (HF) in women who developed HF after receiving anthracyclines or trastuzumab for early stage breast cancer. The results showed that patients with cardiotoxic exposure had fewer comorbidities compared to age-matched controls, and those who developed HF after trastuzumab treatment had a better prognosis than HF controls.

CIRCULATION-HEART FAILURE (2021)

Add to Collection

Article Oncology

Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

Sanaz N. Ghafouri, Rebecca W. Nayeri, Nicholas P. McAndrew, Sara A. Hurvitz

Summary: When compared to anthracycline-sparing regimens, anthracycline-based regimens for the treatment of early TNBC are associated with shorter event-free survival, disease-free survival, and overall survival. This association persists even after adjusting for certain high-risk clinical features.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study

Judy N. Jacobse, Michael Schaapveld, Naomi B. Boekel, Maartje J. Hooning, Agnes Jager, Margreet H. A. Baaijens, Michael Hauptmann, Nicola S. Russell, Emiel J. T. Rutgers, Berthe M. P. Aleman, Gabe S. Sonke, Flora E. van Leeuwen

Summary: The study found that anthracycline-based chemotherapy and trastuzumab treatment may increase the risk of heart failure in young breast cancer patients, especially within the first two years of treatment. Some patients may experience long-term impaired cardiac function after prolonged trastuzumab therapy.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Geosciences, Multidisciplinary

Early Prosperity of Iron Bacteria at the End of the Paleoproterozoic Era

Yifan Qiu, Liping Qin, Fang Huang, Taiping Zhao, Yiliang Li

Summary: This study reports the deposition of iron formation at Yunmengshan, located at the southern margin of the North China Craton, around 1.7 billion years ago. It reveals an increase in atmospheric oxygen level at the end of the Paleoproterozoic era, resulting in enhanced continental oxidative weathering and the early prosperity of microaerophilic Fe(II)-oxidation bacteria on Earth's terrestrial surface.

GEOPHYSICAL RESEARCH LETTERS (2022)

Add to Collection

Article Oncology

Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy

Alis Bonsignore, Thomas H. Marwick, Scott C. Adams, Babitha Thampinathan, Emily Somerset, Eitan Amir, Mike Walker, Husam Abdel-Qadir, C. Anne Koch, Heather J. Ross, Anna Woo, Bernd J. Wintersperger, Mark J. Haykowsky, Paaladinesh Thavendiranathan

Summary: The study identified clinical, cardiac biomarker, and imaging measures associated with reduced cardiorespiratory fitness in breast cancer survivors early post-therapy. A combination of these parameters showed good discrimination in identifying patients with compromised functional independence and potentially increased future CVD risk.

JACC: CARDIOONCOLOGY (2021)

Add to Collection

Review Oncology

The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review

Zihan Si, Yan Zhong, Sixian Lao, Yufeng Wu, Guoping Zhong, Weiwei Zeng

Summary: This review outlines the role of microRNAs (miRNAs) in the treatment of breast cancer using anthracyclines. MiRNAs play important roles in the initiation, development, and treatment of breast cancer, and can influence the efficacy of anthracyclines.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review

James Murray, Hunter Bennett, Eva Bezak, Rebecca Perry

Summary: This systematic review aimed to establish the effect of exercise on global longitudinal strain (GLS) and left ventricular ejection fraction (LVEF) in breast cancer patients undergoing chemotherapy, to determine if exercise can prevent the development of cancer therapy-related cardiac dysfunction (CTRCD). The findings showed that exercise maintained or improved peak oxygen uptake (VO(2)peak) during chemotherapy, while declines were observed in non-exercising groups. Further research is needed to address the methodological limitations in current studies and understand the true effect of exercise in preventing CTRCD.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy

Lulu Cui, Jia Huang, Yongtao Zhan, Ni Qiu, Huan Jin, Jia Li, Huiqi Huang, Hongsheng Li

Summary: The study found that certain genetic polymorphisms may play a role in individual differences in myelosuppression during anthracycline-based chemotherapy. Specific polymorphic alleles were associated with a significantly decreased risk of hematologic toxicity.

LIFE SCIENCES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

TRP Channels: The Neglected Culprits in Breast Cancer Chemotherapy Resistance?

Mayar Soussi, Alice Hasselsweiller, Dimitra Gkika

Summary: Breast cancer is a significant global health concern, and therapy resistance is a major challenge in its treatment. Recent studies have shown that Transient Receptor Potential (TRP) channels play a key role in breast cancer carcinogenesis and resistance to therapy. Targeting these channels may offer a promising approach to overcome therapy resistance in breast cancer patients.

MEMBRANES (2023)

Add to Collection

Article Medicine, General & Internal

Serial Non-Invasive Myocardial Work Measurements for Patient Risk Stratification and Early Detection of Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients: A Single-Centre Observational Study

Ana Moya, Dimitri Buytaert, Monika Beles, Pasquale Paolisso, Juergen Duchenne, Greet Huygh, Ciska Langmans, Adelheid Roelstraete, Sofie Verstreken, Marc Goethals, Riet Dierckx, Jozef Bartunek, Martin Penicka, Guy Van Camp, Ward A. A. Heggermont, Marc Vanderheyden

Summary: This study aims to describe the temporal changes and longitudinal trajectories of Myocardial Work (MW) indices during cardiotoxic treatment. MW indices were calculated through pressure-strain loop (PSL) analysis. Results showed that prior to chemotherapy, MWI, MWE, and CW were significantly lower in patients with moderate Cancer Therapeutics-Related Cardiac Dysfunction (CTRCDmod) than in patients without CTRCD (CTRCDneg) and with mild CTRCD (CTRCDmild). At 6 months, overt cardiac dysfunction in CTRCDmod was accompanied by worse values in MWI, MWE, and WW compared to CTRCDneg and CTRCDmild. MW features such as low baseline CW and a rise in WW at follow-up may indicate risk for CTRCD.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Oncology

Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials

Karama Asleh, Dongsheng Tu, Dongxia Gao, Vivien Bramwell, Mark N. Levine, Kathleen Pritchard, Lois E. Shepherd, Torsten O. Nielsen

Summary: The nestin/INPP4B IHC panel can identify women with basal breast cancers who benefit from nonanthracycline chemotherapy but not endocrine adjuvant treatments. These biomarkers are associated with high grade, younger age, estrogen receptor negativity, triple-negative, core basal, and PAM50 basal-like subtypes.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients

Vincent Aketch Nyangwara, Tinashe Mazhindu, Zedias Chikwambi, Collen Masimirembwa, Thomas B. Campbell, Margaret Borok, Ntokozo Ndlovu

Summary: This study aims to establish the frequency of doxorubicin-induced cardiotoxicity (DIC) in Zimbabwean breast cancer patients and test the predictive power of genetic biomarkers. A cohort of 50 patients were followed up for 12 months and genotyped for UGTA1A6*4, SLC28A3 and RARG. DIC occurred in 11% of the patients. No association between DIC and the three genetic variants was observed. Larger sample size and longer follow-up time are needed for future studies.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Add to Collection

Review Oncology

Breast cancer in the era of integrating Omics approaches

Claudia Rossi, Ilaria Cicalini, Maria Concetta Cufaro, Ada Consalvo, Prabin Upadhyaya, Gianluca Sala, Ivana Antonucci, Piero Del Boccio, Liborio Stuppia, Vincenzo De Laurenzi

Summary: Breast cancer is a heterogeneous disease that requires omics strategies for a better understanding of its mechanisms. High-throughput omics technologies have played a crucial role in breast cancer research, providing new biomarkers and molecular features.

ONCOGENESIS (2022)

Add to Collection

Article Oncology

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

Marie Viala, Marie Vinches, Marie Alexandre, Caroline Mollevi, Anna Durigova, Nadia Hayaoui, Krisztian Homicsko, Alice Cuenant, Celine Gongora, Luca Gianni, Diego Tosi

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl Lewis, Lev Demidov, Mario Mandala, Igor Bondarenko, Paolo A. Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant R. Goodman, Brian Simmons, Chenglin Ye, Yibing Yan, Dirk Schadendorf

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Luca Gianni, Giancarlo Bisagni, Marco Colleoni, Lucia Del Mastro, Claudio Zamagni, Mauro Mansutti, Milvia Zambetti, Antonio Frassoldati, Raffaella De Fato, Pinuccia Valagussa, Giuseppe Viale

LANCET ONCOLOGY (2018)

Add to Collection

Editorial Material Oncology

Is there room for another HER2-targeting drug?

Luca Gianni

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

J. A. Alberro, B. Ballester, P. Deulofeu, R. Fabregas, M. Fraile, J. M. Gubern, J. Janer, A. Moral, J. L. de Pablo, G. Penalva, P. Puig, M. Ramos, R. Rojo, P. Santesteban, C. Serra, M. Sola, L. Solarnau, J. Solsona, E. Veloso, S. Vidal, O. Abe, R. Abe, K. Enomoto, K. Kikuchi, H. Koyama, H. Masuda, Y. Nomura, Y. Ohashi, K. Sakai, K. Sugimachi, M. Toi, T. Tominaga, J. Uchino, M. Yoshida, C. E. Coles, J. L. Haybittle, V. Moebus, C. F. Leonard, G. Calais, P. Garaud, V. Collett, C. Davies, A. Delmestri, J. Sayer, V. J. Harvey, I. M. Holdaway, R. G. Kay, B. H. Mason, J. F. Forbe, P. A. Franci, N. Wilcken, M. Balic, R. Bartsch, C. Fesl, F. Fitzal, H. Fohler, M. Gnant, R. Greil, R. Jakesz, C. Marth, B. Mlineritsch, G. Pfeiler, C. F. Singer, G. G. Steger, H. Stoeger, P. Canney, H. M. A. Yosef, C. Focan, U. Peek, G. D. Oates, J. Powell, M. Durand, L. Mauriac, A. Di Leo, S. Dolci, D. Larsimont, J. M. Nogaret, C. Philippson, M. J. Piccart, M. B. Masood, D. Parker, J. J. Price, M. A. Lindsay, J. Mackey, M. Martin, P. S. G. J. Hupperets, T. Bates, R. W. Blamey, U. Chetty, I. O. Ellis, E. Mallon, D. A. L. Morgan, J. Patnick, S. Pinder, C. Lohrisch, A. Nichol, J. M. S. Bartlett, V. H. Bramwell, B. E. Chen, S. K. L. Chia, K. Gelmon, P. E. Goss, M. N. Levine, W. Parulekar, J. L. Pater, K. I. Pritchard, L. E. Shepherd, D. Tu, T. Whelan, D. Berry, G. Broadwater, C. Cirrincione, H. Muss, L. Norton, R. B. Weiss, H. T. Abu-Zahara, A. Karpov, S. L. Portnoj, S. Bowden, C. Brookes, J. Dunn, I. Fernando, M. Lee, C. Poole, D. Rea, D. Spooner, P. J. Barrett-Lee, R. E. Manse, I. J. Monypenny, N. H. Gordon, H. L. Davis, J. Cuzick, I. Sestak, Y. Lehingue, P. Romestaing, J. B. Dubois, T. Delozier, B. Griffon, J. Mace Lesec'h, G. Mustacchi, L. Petruzelka, O. Pribylova, J. R. Owen, P. Meier, Y. Shan, Y. F. Shao, X. Wang, D. B. Zhao, A. Howell, R. Swindell, J. Albano, C. F. de Oliveira, H. Gervasio, J. Gordilho, B. Ejlertsen, M-B Jensen, H. Mouridsen, R. S. Gelman, J. R. Harris, D. Hayes, C. Henderson, C. L. Shapiro, P. Christiansen, B. Ejlertsen, M. Ewertz, M. B. Jensen, H. T. Mouridsen, T. Fehm, H. J. Trampisch, O. Dalesio, E. G. E. de Vries, S. Rodenhuis, H. van Tinteren, R. L. Comis, N. E. Davidson, R. Gray, N. Robert, G. Sledge, L. J. Solin, J. A. Sparano, D. C. Tormey, W. Wood, D. Cameron, U. Chetty, J. M. Dixon, P. Forrest, W. Jack, I. Kunkler, J. Rossbach, J. G. M. Klijn, A. D. Treurniet-Donker, W. L. J. van Putten, N. Rotmensz, U. Veronesi, G. Viale, H. Bartelink, N. Bijker, J. Bogaerts, F. Cardoso, T. Cufer, J. P. Julien, P. M. Poortmans, E. Rutgers, C. J. H. van de Velde, M. P. Cunningham, R. Huovinen, H. Joensuu, A. Costa, G. Bonadonna, L. Gianni, P. Valagussa, L. J. Goldstein, J. Bonneterre, P. Fargeot, P. Fumoleau, P. Kerbrat, E. Lupors, M. Namer, E. Carrasco, M. Martin, M. A. Segui, W. Eierman, J. Hilfrich, W. Jonat, M. Kaufmann, R. Kreienberg, M. Schumacher, G. Bastert, H. Rauschecker, R. Sauer, W. Sauerbrei, A. Schauer, M. Schumacher, J. U. Blohmer, S. D. Costa, H. Eidtmann, B. Gerber, C. Jackisch, S. Loib, G. von Minckwitz, A. de Schryver, L. Vakaet, M. Belfiglio, A. Nicolucci, F. Pellegrini, M. C. Pirozzoli, M. Sacco, M. Valentini, C. S. McArdle, D. C. Smith, S. Stallard, D. M. Dent, C. A. Gudgeon, A. Hacking, E. Murray, E. Panieri, I. D. Werner, G. L. De Salvo, P. Del Bianco, G. Zavagno, B. Leone, C. T. Vallejo, A. Zwenger, E. Galligioni, M. Lopez, A. Erazo, J. Y. Medina, J. Horiguchi, H. Takei, I. S. Fentiman, J. L. Hayward, R. D. Rubens, D. Skilton, H. Scheurlen, M. Kaufmann, H. C. Sohn, M. Untch, U. Dafni, C. Markopoulos, C. Bamia, G. Fountzilas, G-A Koliou, K. Manousou, D. Mavroudis, P. Klefstrom, C. Blomqvist, T. Saarto, M. Gallen, G. Canavese, C. Tinterri, R. Margreiter, B. de Lafontan, J. Mihura, H. Roche, B. Asselain, R. J. Salmon, J. R. Vilcoq, E. Brain, B. de La Lande, E. Mouret-Fourme, F. Andre, R. Arriagada, S. Delaloge, C. Hill, S. Koscienly, S. Michiels, C. Rubino, R. A'Hern, J. Bliss, P. Ellis, L. Kilburn, J. R. Yarnold, M. Martin, J. Benraadt, M. Kooi, A. O. van de Velde, J. A. van Dongen, J. B. Vermorken, M. Castiglione, A. Coates, M. Colleoni, J. Collins, J. Forbes, R. D. Gelbe, A. Goldhirsch, J. Lindtner, K. N. Price, M. M. Regan, C. M. Rudenstam, H. J. Senn, B. Thuerlimann, J. M. Bliss, C. E. D. Chilvers, R. C. Coombes, E. Hall, M. Marty, M. Buyse, K. Possinger, P. Schmid, M. Untch, D. Wallwiener, L. Foster, W. D. George, H. J. Stewart, P. Stroner, R. Borovik, H. Hayat, M. J. Inbar, T. Peretz, E. Robinson, T. Camerini, F. Formelli, G. Martelli, M. G. Di Mauro, P. Valagussa, F. Perrone, D. Amadori, A. Martoni, F. Pannuti, R. Camisa, A. Musolino, R. Passalacqua, H. Iwata, T. Shien, O. Abe, T. Ikeda, K. Inokuchi, K. Kikuchi, K. Sawa, H. Sonoo, M. Sadoon, A. H. Tulusan, N. Kohno, M. Miyashita, S. Takao, J. -H Ahn, K. H. Jung, S. Korzeniowski, J. Skolyszewski, M. Ogawa, J. Yamashita, E. Bastiaannet, G. J. Liefers, C. J. H. van de Velde, R. Christiaens, P. Neven, R. Paridaens, W. Van den Bogaert, J. C. Gazet, N. Corcoran, N. Deshpande, L. di Martino, P. Douglas, A. Hacking, H. Host, A. Lindtner, G. Notter, A. J. S. Bryant, G. H. Ewing, L. A. Firth, J. L. Krushen-Kosloski, R. Nissen-Meyer, H. Anderson, F. Killander, P. Malmstrom, L. Ryden, L-G Arnesson, J. Carstense, M. Dufmats, H. Fohlin, B. Nordenskjold, M. Soderberg, M. Sundqvist, T. J. Carpenter, N. Murray, G. T. Royle, P. D. Simmonds, K. Albain, W. Barlow, J. Crowley, D. Hayes, J. Gralow, G. Hortobagyi, R. Livingston, S. Martino, C. K. Osborne, P. M. Ravdin, J. Bergh, T. Bondesso, F. Celebiogl, K. Dahlberg, T. Fornander, I. Fredriksson, J. Frisell, E. Goransson, M. Iiristo, U. Johansson, E. Lenner, L. Lofgren, P. Nikolaidis, L. Perbeck, S. Rotstein, K. Sandelin, L. Skoog, G. Svane, E. af Trampe, C. Wadstrom, W. Janni, M. Castiglione, A. Goldhirsch, R. Maibach, H. J. Senn, B. Thurlimann, J. M. S. Bartlett, E. Bastiaannet, P. Hadji, J. Hozumi, D. Rea, C. J. H. van de Velde, K. Holli, K. Rouhento, T. Safra, H. Brenner, A. Hercbergs, M. Yoshimoto, A. H. G. Paterson, K. I. Pritchard, A. Fyles, J. W. Meakin, T. Panzarella, K. I. Pritchard, J. Bahi, S. Delaloge, J. Lemonnier, A. L. Martin, M. Reid, M. Spittle, H. Bishop, N. J. Bundred, J. Cuzick, I. O. Ellis, I. S. Fentiman, J. F. Forbes, S. Forsyth, W. S. George, S. E. Pinder, I. Sestak, G. P. Deutsch, R. Gray, D. L. W. Kwong, V. R. Pai, R. Peto, F. Senanayake, F. Boccardo, A. Rubagotti, M. Baum, S. Forsyth, A. Hackshaw, J. Houghton, J. Ledermann, K. Monson, J. S. Tobias, C. Carlomagno, M. De Laurentiis, S. De Placido, C. Schem, L. Williams, R. Bell, D. Cameron, R. E. Coleman, D. Dodwell, S. Hinsley, H. C. Marshall, D. Hayes, L. J. Pierce, S. M. M. Basso, F. Lumachi, E. Solomayer, R. E. Coleman, J. M. Horsman, J. Lester, M. C. Winter, A. U. Buzdar, L. Hsu, R. R. Love, J. Ahlgren, H. Garmo, L. Holmberg, H. Lindman, F. Warnberg, L. Asmar, S. E. Jones, R. Aft, O. Gluz, N. Harbeck, C. Liedtke, U. Nitz, A. Litton, A. Wallgren, P. Karlsson, B. K. Linderholm, R. T. Chlebowski, H. Caffier, A. M. Brufsky, R. E. Coleman, H. A. Llombart

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial

Luca Gianni, Mauro Mansutti, Antonio Anton, Lourdes Calvo, Giancarlo Bisagni, Begona Bermejo, Vladimir Semiglazov, Marc Thill, Jose Ignacio Chacon, Arlene Chan, Serafin Morales, Isabel Alvarez, Arrate Plazaola, Milvia Zambetti, Andrew D. Redfern, Christian Dittrich, Rebecca Alexandra Dent, Domenico Magazzu, Raffaella De Fato, Pinuccia Valagussa, Ignacio Tusquets

JAMA ONCOLOGY (2018)

Add to Collection

Article Oncology

Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study

Gabriella Mariani, Giulia Galli, Stefano Cavalieri, Pinuccia Valagussa, Giulia Valeria Bianchi, Giuseppe Capri, Sara Cresta, Laura Ferrari, Silvia Damian, Matteo Duca, Filippo de Braud, Angela Moliterni

BREAST JOURNAL (2019)

Add to Collection

Article Oncology

Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

Marc P. E. Andre, Patrice Carde, Simonetta Viviani, Monica Bellei, Catherine Fortpied, Martin Hutchings, Alessandro M. Gianni, Pauline Brice, Olivier Casasnovas, Paolo G. Gobbi, Pier Luigi Zinzani, Jehan Dupuis, Emilio Iannitto, Alessandro Rambaldi, Josette Briere, Laurianne Clement-Filliatre, Marian Heczko, Pinuccia Valagussa, Jonathan Douxfils, Julien Depaus, Massimo Federico, Nicolas Mounier

CANCER MEDICINE (2020)

Add to Collection

Article Oncology

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study

Ian E. Krop, Seock-Ah Im, Carlos Barrios, Herve Bonnefoi, Julie Gralow, Masakazu Toi, Paul A. Ellis, Luca Gianni, Sandra M. Swain, Young-Hyuck Im, Michelino De Laurentiis, Zbigniew Nowecki, Chiun-Sheng Huang, Louis Fehrenbacher, Yoshinori Ito, Jigna Shah, Thomas Boulet, Haiying Liu, Harrison Macharia, Peter Trask, Chunyan Song, Eric P. Winer, Nadia Harbeck

Summary: The purpose of this study was to improve the treatment of high-risk HER2-positive early breast cancer by replacing taxanes and trastuzumab with T-DM1. The study found that there was no significant difference in disease-free survival between the two treatment arms, but the T-DM1 group had a lower treatment completion rate.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Treatment landscape of triple-negative breast cancer - expanded options, evolving needs

Giampaolo Bianchini, Carmine De Angelis, Luca Licata, Luca Gianni

Summary: Recent advances in omics technologies have improved our understanding of the heterogeneity and microenvironment of triple-negative breast cancers (TNBCs), supporting a view of this breast cancer subtype as an ecosystem that encompasses both intrinsic and extrinsic features of cancer cells. The authors of this Review describe the current and upcoming therapeutic landscape of TNBC and discuss how an integrated view of the TNBC ecosystem can provide improved opportunities for tailoring treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

Sandra M. Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara A. Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song, Patricia Cortazar

Summary: The study aimed to evaluate the outcomes and recurrence risks for patients with HER2-positive early breast cancer who achieved pathological complete response (pCR) after neoadjuvant HER2-targeted therapy plus chemotherapy. The results showed that patients treated with dual HER2-targeted therapy in both the neoadjuvant and adjuvant settings had the highest 4-year event-free survival rates, suggesting that this treatment approach may provide the most benefit for patients with HER2-positive early breast cancer.

CANCERS (2022)

Add to Collection

Article Oncology

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Marion van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E. Geyer, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Herve Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard Gelber, Coralie Poncet, Pierre Squifflet, Everardo D. Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar

Summary: Achieving pCR is important for the prognosis of EFS and OS in patients with early breast cancer. This study investigates prognostic factors for EFS and OS in patients with and without pCR after neoadjuvant therapy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

J. Bergh, K. Pritchard, S. Swain, D. Cameron, K. Albain, S. Anderson, R. Arriagada, J. Bartlett, E. Bergsten-Nordstrom, J. Bliss, R. Bradley, E. Brain, J. Braybrooke, L. Carey, M. Clarke, R. Coleman, J. Cuzick, N. Davidson, L. Del Mastro, A. Di Leo, J. Dignam, D. Dodwell, M. Dowsett, F. Duane, B. Ejlertsen, P. Francis, R. Gelber, M. Gnant, M. Goetz, P. Goodwin, R. Gray, P. Halpin-Murphy, D. Hayes, C. Hill, R. Jagsi, W. Janni, Z. Liu, S. Loibl, E. MacKinnon, E. Mamounas, G. Mannu, M. Martin, P. McGale, H. Mukai, V Nekljudova, L. Norton, Y. Ohashi, H. Pan, R. Peto, M. Piccart, L. Pierce, P. Poortmans, V Raina, D. Rea, M. Regan, J. Robertson, E. Rutgers, D. Slamon, T. Spanic, J. Sparano, G. Steger, C. Taylor, G. Tang, M. Toi, A. Tutt, G. Viale, X. Wang, T. Whelan, N. Wilcken, N. Wolmark

Summary: The study demonstrates that adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer significantly reduces the risk of breast cancer recurrence and death, with worthwhile proportional reductions irrespective of recorded patient and tumor characteristics.

LANCET ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial

Michele Reni, Gianpaolo Balzano, Silvia Zanon, Alessandro Zerbi, Lorenza Rimassa, Renato Castoldi, Domenico Pinelli, Stefania Mosconi, Claudio Doglioni, Marta Chiaravalli, Chiara Pircher, Paolo Giorgio Arcidiacono, Valter Torri, Paola Maggiora, Domenica Ceraulo, Massimo Falconi, Luca Gianni

LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)

Add to Collection

No Data Available

Anthracyclines and Early Breast Cancer: The End of an Era?

Journal

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper